

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 9887)

**POLL RESULTS OF
THE EXTRAORDINARY GENERAL MEETING
HELD ON DECEMBER 17, 2025**

The board (the “**Board**”) of directors of Nanjing Leads Biolabs Co., Ltd. (the “**Company**”) announces that at the extraordinary general meeting of the Company (the “**EGM**”) held on December 17, 2025, the proposed resolutions as set out in the notice of the EGM (“**Notice of the EGM**”) were duly passed by the Shareholders of the Company by way of poll. Unless otherwise stated, capitalized terms used herein shall have the same meanings as those defined in the circular of the Company dated November 28, 2025 (the “**Circular**”).

The poll results taken at the EGM were as follows:

Special Resolutions		Number of Votes (Approximate %)		
		For	Against	Abstain
1.	To consider and if thought fit, pass with or without amendments, the proposed adoption of the H Share Award Scheme.	118,018,494 (89.28%)	12,196,841 (9.23%)	1,971,996 (1.49%)
2.	To consider and if thought fit, pass with or without amendments, the proposed authorization to the Board and/or the Delegatee to handle matters in relation to the H Share Award Scheme.	109,019,016 (82.47%)	12,182,341 (9.22%)	10,985,974 (8.31%)

Special Resolutions		Number of Votes (Approximate %)		
		For	Against	Abstain
3.	To consider and, if thought fit, pass with or without amendments, the following resolution as a special resolution: THAT: (a) subject to and conditional upon the Listing Committee of the Stock Exchange granting approval for the listing of, and permission to deal in, the Shares which may fall to be issued and allotted pursuant to awards which may be granted under the H Share Award Scheme, the H Share Award Schemes be and are hereby approved and adopted; (b) the total number of new Shares to be allotted and issued pursuant to the H Share Award Scheme shall not exceed such number of Shares as equals to 5% of the Shares in issue as at the date of passing of this resolution; and (c) the Directors be and are hereby authorized to do all such acts and to enter into all such arrangements as may be necessary or expedient in order to give full effect to the H Share Award Scheme, including but without limitation to: (i) grant awards under H Share Award Scheme and to allot and issue from time to time such number of Shares as may be required to be issued and/or transferred pursuant to the H Share Award Scheme and subject to the Listing Rules; (ii) make application at the appropriate time or times to the Listing Committee of the Stock Exchange and any other stock exchanges upon which the issued Shares may, for the time being, be listed, for listing of, and permission to deal in, any Shares which may hereafter from time to time be allotted and issued pursuant to the Share Schemes; and (iii) consent, if it so deems fit and expedient, to such conditions, modifications and/or variations as may be required or imposed by the relevant authorities in relation to the H Share Award Scheme.	109,004,516 (82.46%)	12,196,841 (9.23%)	10,985,974 (8.31%)
4.	To consider and approve the Service Provider Sublimit as defined in the H Share Award Scheme, subject to the adoption of the H Share Award Scheme.	108,846,016 (82.34%)	12,355,341 (9.35%)	10,985,974 (8.31%)
5.	To consider and approve the proposed cancellation of the Supervisory Committee and amendments to the Articles of Association.	123,381,853 (93.34%)	0 (0.00%)	8,805,478 (6.66%)

Notes:

- (1) For details, please refer to the Circular.

As majority of more than two-thirds of the votes were cast in favor of resolutions above, such resolutions were duly passed as special resolutions.

- (2) As at the date of the EGM, (i) the total number of issued Shares of the Company was 198,891,800 Shares, including 45,613,109 Unlisted Shares and 153,278,691 H Shares; and (ii) there were no treasury Shares (including any treasury share deposited with CCASS) or repurchased share pending cancellation held by the Company.

Accordingly, the total number of Shares entitling the holders thereof to attend and vote on the resolution at the EGM was 198,891,800 Shares. The Shareholders and their proxies present at the EGM hold a total of 132,187,331 Shares carrying voting rights of the Company, representing approximately 66.46% of the number of total issued Shares of the Company.

- (3) There were no Shares entitling the holders thereof to attend and abstain from voting in favour of the resolution at the EGM as set out in Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).
- (4) No Shareholder was required under the Listing Rules to abstain from voting on any resolution proposed at the EGM. No Shareholder of the Company has stated his intention in the Circular to vote against or to abstain from voting on the resolution at the EGM.
- (5) The Company’s H Share Registrar, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer for the vote-taking at the EGM.
- (6) The executive directors, Dr. Kang Xiaoqiang, Dr. Lai Shoupeng and Mr. Zuo Honggang, non-executive directors, Mr. Zhang Yincheng and Dr. Chen Renhai, and independent non-executive directors, Dr. Zhang Hongbing, Mr. Du Yilong and Ms. Du Jiliu attended the EGM either in person or by electronic means.

By order of the Board
Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司
Dr. KANG XIAOQIANG
*Chairman, Executive Director and
Chief Executive Officer*

Nanjing, PRC, December 17, 2025

As at the date of this announcement, the board of directors of the Company comprises: (i) Dr. Kang Xiaoqiang (Chairman of the Board), Dr. Lai Shoupeng and Mr. Zuo Honggang as executive Directors; (ii) Mr. Zhang Yincheng, Dr. Chen Renhai and Dr. Ni Jia as non-executive Directors; and (iii) Dr. Zhang Hongbing, Mr. Du Yilong and Ms. Du Jiliu as independent non-executive Directors.